Zheng-Rong Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zheng-Rong Lu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Dennis L. Parker
Department of Radiology, University of Utah, Salt Lake City, UT 84108, USA
9 shared publicationsEun-Kee Jeong
Department of Radiology, University of Utah, Salt Lake City, UT 84108, USA
9 shared publicationsYi Feng
Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, USA
6 shared publicationsTianyi Ke
Departments of Pharmaceutics and Pharmaceutical Chemistry
5 shared publicationsYuda Zong
Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84108, USA
5 shared publications- Aaron M. Mohs
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198-6858, USA
4 shared publications
Latest Publications
- 8 June 2009
- Published by Springer Nature
- p. 581-599
Image-Guided Photodynamic Cancer Therapy
- 31 May 2009
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 27 (4) , 503-511
Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents
- 31 May 2009
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 27 (4) , 503-511
Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents
- Open Access
- 3 December 2008
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 19 (12) , 2300-2303
A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI
A peptide targeted contrast agent, CLT1-(Gd-DTPA), was synthesized for molecular imaging of fibronectin−fibrin complexes in tumor tissue with magnetic resonance imaging (MRI). The T1 and T2 relaxivities of CLT1-(Gd-DTPA) were 4.22 and 4.45 mM−1 s−1 at 3 T, respectively. The targeted contrast agent specifically bound to tumor tissue and resulted in significant tumor contrast enhancement at a dose of 0.1 mmol Gd/kg for at least 60 min in mice bearing HT-29 human colon carcinoma xenografts as shown in dynamic MR images. In contrast, a control nontargeted contrast agent, Gd(DTPA-BMA), was cleared rapidly with little tumor enhancement 60 min postinjection. Tumor enhancement with CLT1-(Gd-DTPA) was significantly reduced after coinjection with a 3-fold excess of free CLT1 peptide. The preliminary study has shown that CLT1-(Gd-DTPA) can specifically bind to the fibrin−fibronectin complexes in tumor tissues, resulting in significant tumor enhancement. The targeted contrast agent has a potential for cancer molecular imaging with MRI.
- 3 December 2008
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 19 (12) , 2300-2303
Open AccessA Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI
A peptide targeted contrast agent, CLT1-(Gd-DTPA), was synthesized for molecular imaging of fibronectin−fibrin complexes in tumor tissue with magnetic resonance imaging (MRI). The T1 and T2 relaxivities of CLT1-(Gd-DTPA) were 4.22 and 4.45 mM−1 s−1 at 3 T, respectively. The targeted contrast agent specifically bound to tumor tissue and resulted in significant tumor contrast enhancement at a dose of 0.1 mmol Gd/kg for at least 60 min in mice bearing HT-29 human colon carcinoma xenografts as shown in dynamic MR images. In contrast, a control nontargeted contrast agent, Gd(DTPA-BMA), was cleared rapidly with little tumor enhancement 60 min postinjection. Tumor enhancement with CLT1-(Gd-DTPA) was significantly reduced after coinjection with a 3-fold excess of free CLT1 peptide. The preliminary study has shown that CLT1-(Gd-DTPA) can specifically bind to the fibrin−fibronectin complexes in tumor tissues, resulting in significant tumor enhancement. The targeted contrast agent has a potential for cancer molecular imaging with MRI.
- Open Access
- 24 November 2008
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 60 (6) , 1347-1352
Characterization of tumor angiogenesis with dynamic contrast‐enhanced MRI and biodegradable macromolecular contrast agents in mice
The efficacy of polydisulfide‐based biodegradable macromolecular contrast agents for characterizing tumor angiogenesis was investigated in a mouse model using dynamic contrast‐enhanced MRI (DCE‐MRI). Biodegradable macromolecular MRI contrast agents, gadopentetate dimeglumine (Gd‐DTPA) cystamine copolymers (GDCC), and Gd‐DTPA cystine copolymers (GDCP), with molecular weights of 20 and 70 kDa were used in the study. Gadodiamide (Gd [DTPA‐BMA]) and albumin labeled with Gd‐DTPA [albumin‐(Gd‐DTPA)] were used as the controls. The DCE‐MRI studies were performed in nude mice bearing prostate tumor xenografts from the MDA‐PCa‐2b cell line. Tumor angiogenic kinetic parameters, including endothelial transfer coefficient (KPS), fractional tumor plasma volume (fPV), and permeability surface area product (PS), were estimated from the DCE‐MRI data using a two‐compartment model. The KPS and fPV values estimated by the biodegradable macromolecular contrast agents were between those estimated by Gd(DTPA‐BMA) and albumin‐(Gd‐DTPA). The parameters estimated by the agent with a slow degradation rate and high molecular weight, GDCP‐70 (KPS = 2.09 ± 0.50 ml/min/100 cc and fPV = 0.075 ± 0.021), were closer to those by albumin‐(Gd‐DTPA) (KPS = 1.43 ± 0.64 ml/min/100 cc and fPV = 0.044 ± 0.007) than by other agents with relatively low molecular weight or rapid degradation rate. The polydisulfide‐based biodegradable macromolecular contrast agents are promising for characterizing tumor vascularity and angiogenesis with DCE‐MRI. Magn Reson Med 60:1347–1352, 2008.
- 24 November 2008
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 60 (6) , 1347-1352
Open AccessCharacterization of tumor angiogenesis with dynamic contrast‐enhanced MRI and biodegradable macromolecular contrast agents in mice
The efficacy of polydisulfide‐based biodegradable macromolecular contrast agents for characterizing tumor angiogenesis was investigated in a mouse model using dynamic contrast‐enhanced MRI (DCE‐MRI). Biodegradable macromolecular MRI contrast agents, gadopentetate dimeglumine (Gd‐DTPA) cystamine copolymers (GDCC), and Gd‐DTPA cystine copolymers (GDCP), with molecular weights of 20 and 70 kDa were used in the study. Gadodiamide (Gd [DTPA‐BMA]) and albumin labeled with Gd‐DTPA [albumin‐(Gd‐DTPA)] were used as the controls. The DCE‐MRI studies were performed in nude mice bearing prostate tumor xenografts from the MDA‐PCa‐2b cell line. Tumor angiogenic kinetic parameters, including endothelial transfer coefficient (KPS), fractional tumor plasma volume (fPV), and permeability surface area product (PS), were estimated from the DCE‐MRI data using a two‐compartment model. The KPS and fPV values estimated by the biodegradable macromolecular contrast agents were between those estimated by Gd(DTPA‐BMA) and albumin‐(Gd‐DTPA). The parameters estimated by the agent with a slow degradation rate and high molecular weight, GDCP‐70 (KPS = 2.09 ± 0.50 ml/min/100 cc and fPV = 0.075 ± 0.021), were closer to those by albumin‐(Gd‐DTPA) (KPS = 1.43 ± 0.64 ml/min/100 cc and fPV = 0.044 ± 0.007) than by other agents with relatively low molecular weight or rapid degradation rate. The polydisulfide‐based biodegradable macromolecular contrast agents are promising for characterizing tumor vascularity and angiogenesis with DCE‐MRI. Magn Reson Med 60:1347–1352, 2008.
- 5 September 2008
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 9 (10) , 2742-2748
Synthesis and Evaluation of Globular Gd-DOTA-Monoamide Conjugates with Precisely Controlled Nanosizes for Magnetic Resonance Angiography
The purpose of this study was to design and prepare macromolecular contrast agents (CAs) with a precisely defined globular structure for MR angiography and tumor angiogenesis imaging. Generations 1 through 3 (Gd-DOTA-monoamide)-poly-l-lysine octasilsesquioxane dendrimers were prepared as nanoglobular MRI CAs. The nanoglobular Gd(III) chelates had a well-defined compact globular structure and high loading of Gd-DOTA-monoamide at their surface. The size of the G1, G2, and G3 nanoglobular MRI CAs was approximately 2.0, 2.4, and 3.2 nm, respectively. The T1 relaxivity of G1, G2, and G3 nanoglobular MRI CAs was approximately 6.4, 7.2, and 10.0 mM−1 sec−1 at 3T, respectively. The nanoglobular MRI CAs showed size-dependent contrast enhancement within the mouse vasculature, which gradually decayed to baseline after a 60 min session. The G3 nanoglobular CA resulted in more significant and prolonged vascular enhancement than the smaller nanoglobular agents at 0.03 mmol Gd/kg. The G3 agent also provided significant and prolonged contrast enhancement in the heart and vasculature at a dose as low as 0.01 mmol Gd/kg, 1/10th of the regular clinical dose. Significant enhancement was observed in tumor for all CAs. The nanoglobular CAs cleared via renal filtration and accumulated in the urinary bladder as shown in the dynamic MR images. The nanoglobular Gd(III) chelates are effective intravascular MRI CAs at substantially reduced doses. The nanoglobular MRI CAs are promising for further preclinical development for MR angiography and MR imaging of tumor angiogenesis.
- 5 September 2008
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 9 (10) , 2742-2748
Synthesis and Evaluation of Globular Gd-DOTA-Monoamide Conjugates with Precisely Controlled Nanosizes for Magnetic Resonance Angiography
The purpose of this study was to design and prepare macromolecular contrast agents (CAs) with a precisely defined globular structure for MR angiography and tumor angiogenesis imaging. Generations 1 through 3 (Gd-DOTA-monoamide)-poly-l-lysine octasilsesquioxane dendrimers were prepared as nanoglobular MRI CAs. The nanoglobular Gd(III) chelates had a well-defined compact globular structure and high loading of Gd-DOTA-monoamide at their surface. The size of the G1, G2, and G3 nanoglobular MRI CAs was approximately 2.0, 2.4, and 3.2 nm, respectively. The T1 relaxivity of G1, G2, and G3 nanoglobular MRI CAs was approximately 6.4, 7.2, and 10.0 mM−1 sec−1 at 3T, respectively. The nanoglobular MRI CAs showed size-dependent contrast enhancement within the mouse vasculature, which gradually decayed to baseline after a 60 min session. The G3 nanoglobular CA resulted in more significant and prolonged vascular enhancement than the smaller nanoglobular agents at 0.03 mmol Gd/kg. The G3 agent also provided significant and prolonged contrast enhancement in the heart and vasculature at a dose as low as 0.01 mmol Gd/kg, 1/10th of the regular clinical dose. Significant enhancement was observed in tumor for all CAs. The nanoglobular CAs cleared via renal filtration and accumulated in the urinary bladder as shown in the dynamic MR images. The nanoglobular Gd(III) chelates are effective intravascular MRI CAs at substantially reduced doses. The nanoglobular MRI CAs are promising for further preclinical development for MR angiography and MR imaging of tumor angiogenesis.
- 27 June 2008
- Published by Springer Nature in Pharmaceutical Research
- Vol. 25 (9) , 2002-2011
Contrast-Enhanced MRI-Guided Photodynamic Cancer Therapy with a Pegylated Bifunctional Polymer Conjugate
Purpose To study contrast-enhanced MRI guided photodynamic therapy with a pegylated bifunctional polymer conjugate containing an MRI contrast agent and a photosensitizer for minimally invasive image-guided cancer treatment. Methods Pegylated and non-pegylated poly-(l-glutamic acid) conjugates containing mesochlorin e6, a photosensitizer, and Gd(III)-DO3A, an MRI contrast agent, were synthesized. The effect of pegylation on the biodistribution and tumor targeting was non-invasively visualized in mice bearing MDA-MB-231 tumor xenografts with MRI. MRI-guided photodynamic therapy was carried out in the tumor bearing mice. Tumor response to photodynamic therapy was evaluated by dynamic contrast enhanced MRI and histological analysis. Results The pegylated conjugate had longer blood circulation, lower liver uptake and higher tumor accumulation than the non-pegylated conjugate as shown by MRI. Site-directed laser irradiation of tumors resulted in higher therapeutic efficacy for the pegylated conjugate than the non-pegylated conjugate. Moreover, animals treated with photodynamic therapy showed reduced vascular permeability on DCE-MRI and decreased microvessel density in histological analysis. Conclusions Pegylation of the polymer bifunctional conjugates reduced non-specific liver uptake and increased tumor uptake, resulting in significant tumor contrast enhancement and high therapeutic efficacy. The pegylated poly(l-glutamic acid) bifunctional conjugate is promising for contrast enhanced MRI guided photodynamic therapy in cancer treatment.
- 27 June 2008
- Published by Springer Nature in Pharmaceutical Research
- Vol. 25 (9) , 2002-2011
Contrast-Enhanced MRI-Guided Photodynamic Cancer Therapy with a Pegylated Bifunctional Polymer Conjugate
Purpose To study contrast-enhanced MRI guided photodynamic therapy with a pegylated bifunctional polymer conjugate containing an MRI contrast agent and a photosensitizer for minimally invasive image-guided cancer treatment. Methods Pegylated and non-pegylated poly-(l-glutamic acid) conjugates containing mesochlorin e6, a photosensitizer, and Gd(III)-DO3A, an MRI contrast agent, were synthesized. The effect of pegylation on the biodistribution and tumor targeting was non-invasively visualized in mice bearing MDA-MB-231 tumor xenografts with MRI. MRI-guided photodynamic therapy was carried out in the tumor bearing mice. Tumor response to photodynamic therapy was evaluated by dynamic contrast enhanced MRI and histological analysis. Results The pegylated conjugate had longer blood circulation, lower liver uptake and higher tumor accumulation than the non-pegylated conjugate as shown by MRI. Site-directed laser irradiation of tumors resulted in higher therapeutic efficacy for the pegylated conjugate than the non-pegylated conjugate. Moreover, animals treated with photodynamic therapy showed reduced vascular permeability on DCE-MRI and decreased microvessel density in histological analysis. Conclusions Pegylation of the polymer bifunctional conjugates reduced non-specific liver uptake and increased tumor uptake, resulting in significant tumor contrast enhancement and high therapeutic efficacy. The pegylated poly(l-glutamic acid) bifunctional conjugate is promising for contrast enhanced MRI guided photodynamic therapy in cancer treatment.
- 1 October 2007
- Published by Elsevier in Journal of Controlled Release
- Vol. 122 (3) , 269-277
Polymer platforms for drug delivery and biomedical imaging
- 1 October 2007
- Published by Elsevier in Journal of Controlled Release
- Vol. 122 (3) , 269-277
Polymer platforms for drug delivery and biomedical imaging
- 17 August 2007
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 4 (5) , 759-768
Synthesis, Characterization, and Gene Delivery of Poly-l-lysine Octa(3-aminopropyl)silsesquioxane Dendrimers: Nanoglobular Drug Carriers with Precisely Defined Molecular Architectures
Macromolecules with defined nanosizes—nanoglobules—were synthesized and characterized as novel drug carriers with precise molecular architectures. Poly-l-lysine dendrimers with a cubic octa(3-aminopropyl)silsesquioxane (OAS) core, (l-lysine)8-OAS, (l-lysine)16-(l-lysine)8-OAS, (l-lysine)32-(l-lysine)16-(l-lysine)8-OAS, and (l-lysine)64-(l-lysine)32-(l-lysine)16-(l-lysine)8-OAS, were divergently synthesized by solution phase peptide chemistry in good yield and purity. Matrix-assisted laser desorption time of flight (MALDI-TOF) mass spectrometry showed complete substitution of the surface amino groups of lower generation dendrimers during synthesis, as well as precisely defined molecular architectures of the nanoglobules. The structures of the nanoglobules were further characterized by 1H- and 13C-NMR and 2D-NMR (correlation spectroscopy (COSY) and pulsed-field-gradient heteronuclear multiple quantum correlation (gHMQC)) spectroscopy. The 1H-NMR spectroscopy revealed that the nanoglobules had a relatively rigid molecular architecture. Cytotoxicity studies showed that these nanoglobules exhibited a size-dependent toxicity, but it was much lower than that of linear poly-l-lysine. Preliminary in vitro nucleic acid delivery studies have shown that these globular dendrimers can efficiently deliver plasmid DNA to MDA-MB-231 cells. These nanoglobules hold much promise as safe drug carriers with precisely defined molecular architecture.
- 17 August 2007
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 4 (5) , 759-768
Synthesis, Characterization, and Gene Delivery of Poly-l-lysine Octa(3-aminopropyl)silsesquioxane Dendrimers: Nanoglobular Drug Carriers with Precisely Defined Molecular Architectures
Macromolecules with defined nanosizes—nanoglobules—were synthesized and characterized as novel drug carriers with precise molecular architectures. Poly-l-lysine dendrimers with a cubic octa(3-aminopropyl)silsesquioxane (OAS) core, (l-lysine)8-OAS, (l-lysine)16-(l-lysine)8-OAS, (l-lysine)32-(l-lysine)16-(l-lysine)8-OAS, and (l-lysine)64-(l-lysine)32-(l-lysine)16-(l-lysine)8-OAS, were divergently synthesized by solution phase peptide chemistry in good yield and purity. Matrix-assisted laser desorption time of flight (MALDI-TOF) mass spectrometry showed complete substitution of the surface amino groups of lower generation dendrimers during synthesis, as well as precisely defined molecular architectures of the nanoglobules. The structures of the nanoglobules were further characterized by 1H- and 13C-NMR and 2D-NMR (correlation spectroscopy (COSY) and pulsed-field-gradient heteronuclear multiple quantum correlation (gHMQC)) spectroscopy. The 1H-NMR spectroscopy revealed that the nanoglobules had a relatively rigid molecular architecture. Cytotoxicity studies showed that these nanoglobules exhibited a size-dependent toxicity, but it was much lower than that of linear poly-l-lysine. Preliminary in vitro nucleic acid delivery studies have shown that these globular dendrimers can efficiently deliver plasmid DNA to MDA-MB-231 cells. These nanoglobules hold much promise as safe drug carriers with precisely defined molecular architecture.
- Open Access
- 20 July 2007
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 58 (1) , 110-118
Modification of Gd‐DTPA cystine copolymers with PEG‐1000 optimizes pharmacokinetics and tissue retention for magnetic resonance angiography
The purpose of this study was to investigate the effect of PEGylation of novel biodegradable macromolecular polydisulfide Gd(III) complexes, gadolinium diethylenetriaminepentaacetate (GdDTPA) cystine copolymers (GDCP), on their pharmacokinetics and long‐term Gd(III) tissue retention, and to demonstrate the potential application of PEGylated GDCP (PEG‐GDCP) for MR angiography (MRA). The pharmacokinetics, biodistribution, and metabolic excretion of PEG1000‐GDCP (42.1–52.1 kDa; PEG: MW = 1000 Da) with three different PEG grafting degrees and GDCP (43.3 kDa) were investigated in Sprague‐Dawley rats. Pharmacokinetic data were analyzed by means of an open two‐compartment model. Initially all three PEG1000‐GDCP contrast agents (CAs) had a higher plasma concentration than GDCP, but after 30 min the Gd(III) concentration from the PEGylated agents rapidly decreased, resulting in significantly lower elimination half‐life values. All of the biodegradable macromolecular CAs demonstrated low long‐term Gd(III) tissue accumulation, while PEG1000‐GDCP had significantly lower accumulation in the liver than GDCP. In the rats, all CAs showed excellent vascular contrast enhancement in an MRA protocol with a long image acquisition time. Because PEG1000‐GDCP remained intravascular for an acceptable period for effective contrast‐enhanced (CE)‐MRA, and then excreted rapidly from the vasculature with minimal tissue retention, PEG1000‐GDCP shows a great promise as a blood‐pool CA for MRA. Magn Reson Med 58:110–118, 2007.
- 20 July 2007
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 58 (1) , 110-118
Open AccessModification of Gd‐DTPA cystine copolymers with PEG‐1000 optimizes pharmacokinetics and tissue retention for magnetic resonance angiography
The purpose of this study was to investigate the effect of PEGylation of novel biodegradable macromolecular polydisulfide Gd(III) complexes, gadolinium diethylenetriaminepentaacetate (GdDTPA) cystine copolymers (GDCP), on their pharmacokinetics and long‐term Gd(III) tissue retention, and to demonstrate the potential application of PEGylated GDCP (PEG‐GDCP) for MR angiography (MRA). The pharmacokinetics, biodistribution, and metabolic excretion of PEG1000‐GDCP (42.1–52.1 kDa; PEG: MW = 1000 Da) with three different PEG grafting degrees and GDCP (43.3 kDa) were investigated in Sprague‐Dawley rats. Pharmacokinetic data were analyzed by means of an open two‐compartment model. Initially all three PEG1000‐GDCP contrast agents (CAs) had a higher plasma concentration than GDCP, but after 30 min the Gd(III) concentration from the PEGylated agents rapidly decreased, resulting in significantly lower elimination half‐life values. All of the biodegradable macromolecular CAs demonstrated low long‐term Gd(III) tissue accumulation, while PEG1000‐GDCP had significantly lower accumulation in the liver than GDCP. In the rats, all CAs showed excellent vascular contrast enhancement in an MRA protocol with a long image acquisition time. Because PEG1000‐GDCP remained intravascular for an acceptable period for effective contrast‐enhanced (CE)‐MRA, and then excreted rapidly from the vasculature with minimal tissue retention, PEG1000‐GDCP shows a great promise as a blood‐pool CA for MRA. Magn Reson Med 58:110–118, 2007.
- 1 June 2007
- Vol. 2 (2) , 191-199
RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker ανβ3 integrin with MR T1 mapping
Cyclic Arg-Gly-Asp-D-Phe-Lys [c(RGDfK)] targeted poly(L-glutamic acid) (PGA)-(Gd-DO3A) conjugate with a biodegradable cystamine spacer was prepared and evaluated for in vivo detection of an angiogenesis biomarker, ανβ3 integrin, in neoplastic tissues with T1 mapping, a quantitative magnetic resonance imaging (MRI) technique. The binding activity of the c(RGDfK) containing conjugate was investigated using in vitro vitronectin assay with human prostate carcinoma DU145 cell line and Kaposi’s sarcoma SLK cell line. The peptide c(RGDfK) and PGA-cystamine-(Gd-DO3A) conjugate were used as controls. The binding affinity of polymer bound c(RGDfK) was slightly lower than free c(RGDfK) peptide. The RGD targeted conjugate had higher binding affinity to the DU145 cells than the SLK cells, which was consistent to free c(RGDfK). The imaging of ανβ3 integrin with targeted PGA-cystamine-(Gd-DO3A) was evaluated in nude mice bearing DU145 and SLK xenografts at a dose of 5 μmol-Gd/kg. The targeted conjugate demonstrated higher in vivo binding affinity to the DU145 xenografts than the SLK xenografts, resulting in a significant decrease of T1 values of water protons in the periphery of the DU145 tumors as shown in the MR T1 maps. No significant decrease of T1 values was observed in the SLK tumor with the targeted conjugate and in both tumors with the non-targeted conjugate. The targeted polymeric Gd(III) chelate conjugate with a degradable spacer has the potential to be a new paradigm for safe and effective probes in molecular imaging with quantitative MR T1 mapping.
- 1 June 2007
- Vol. 2 (2) , 191-199
RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker ανβ3 integrin with MR T1 mapping
Cyclic Arg-Gly-Asp-D-Phe-Lys [c(RGDfK)] targeted poly(L-glutamic acid) (PGA)-(Gd-DO3A) conjugate with a biodegradable cystamine spacer was prepared and evaluated for in vivo detection of an angiogenesis biomarker, ανβ3 integrin, in neoplastic tissues with T1 mapping, a quantitative magnetic resonance imaging (MRI) technique. The binding activity of the c(RGDfK) containing conjugate was investigated using in vitro vitronectin assay with human prostate carcinoma DU145 cell line and Kaposi’s sarcoma SLK cell line. The peptide c(RGDfK) and PGA-cystamine-(Gd-DO3A) conjugate were used as controls. The binding affinity of polymer bound c(RGDfK) was slightly lower than free c(RGDfK) peptide. The RGD targeted conjugate had higher binding affinity to the DU145 cells than the SLK cells, which was consistent to free c(RGDfK). The imaging of ανβ3 integrin with targeted PGA-cystamine-(Gd-DO3A) was evaluated in nude mice bearing DU145 and SLK xenografts at a dose of 5 μmol-Gd/kg. The targeted conjugate demonstrated higher in vivo binding affinity to the DU145 xenografts than the SLK xenografts, resulting in a significant decrease of T1 values of water protons in the periphery of the DU145 tumors as shown in the MR T1 maps. No significant decrease of T1 values was observed in the SLK tumor with the targeted conjugate and in both tumors with the non-targeted conjugate. The targeted polymeric Gd(III) chelate conjugate with a degradable spacer has the potential to be a new paradigm for safe and effective probes in molecular imaging with quantitative MR T1 mapping.